Author

Xu Shi

University of MichiganORCID 0000-0001-8566-9552Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 2 Biochemistry· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:statistical model· 3 Research Focus:benchmarking· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Approach:benchmark study· 1 Assay:bulk RNA-seq· 1

Frequent Co-Authors

Robert Edgardo GerszteniD· 2 shared Aik Choon TaniD· 1 shared April P. CarsoniD· 1 shared Bertha HidalgoiD· 1 shared Charleen D. AdamsiD· 1 shared Chisayo KozukaiD· 1 shared Christopher M. Mulla· 1 shared Chuan WangiD· 1 shared

Activity by Year

2022-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

Robert Edgardo GersztenORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A small molecule PTER-selective inhibitor reduces food intake and body weight

Sipei Fu, Lushun Wang, Veronica L. Li, Xuchao Lyu, Wei Wei, Xu Shi, Shuliang Deng, Jacob L. Barber, Usman A. Tahir, Charleen D. Adams, April P. Carson, Bertha Hidalgo, Laura M. Raffield, James G. Wilson, Hlib Razumkov, , Jonathan Z. Long

This study identifies a PTER inhibitor that reduces food intake and body weight in mice, linking PTER function to obesity treatment.

Cell chemical biology · Mar 1, 2026Peer-reviewedBiochemistry

A real-world cohort study of immune-related adverse events in patients receiving immune checkpoint inhibitors

Yanfei Wang, Yi Maggie Guo, Aik Choon Tan, Lili Zhao, Xu Shi, Yong Chen, Ramon C. Sun, Mei Liu, Jing Su, Thomas J. George, Jiang Bian, Qianqian Song

This study identifies risk factors and patterns of immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors using real-world data.

npj Precision Oncology · Nov 11, 2025Peer-reviewedGenetic & Genomic Medicine

MRSL: A phenome-wide causal discovery algorithm based on GWAS summary data

Lei Hou, Zhi Geng, Xu Shi, Chuan Wang, Hongkai Li, Fuzhong Xue

MRSL uses GWAS summary data to discover causal relationships between biomarkers and diseases, achieving higher accuracy and speed than existing methods.

medRxiv · Jun 29, 2022 · PreprintGenetic & Genomic Medicine

Bromodomain inhibition reveals FGF15/19 as a target of epigenetic regulation and metabolic control

Chisayo Kozuka, Vissarion Efthymiou, Vicência Sales, Liyuan Zhou, Soravis Alm Osataphan, Yixing Yuchi, JEREMY I. CHIMENE-WEISS, Christopher M. Mulla, ELVIRA M. ISGANAITIS, Jessica Desmond, Suzuka Sanechika, Joji Kusuyama, Laurie J. Goodyear, Xu Shi, Robert Edgardo Gerszten, , Mary‐Elizabeth Patti

The paper shows that inhibiting bromodomain proteins like BRD4 reduces FGF15/19 expression, leading to hyperglycemia, and that overexpressing FGF19 can reverse these effects.

Diabetes · Jan 31, 2022Peer-reviewedSystems Biology